Amy Conrad

Contacto de Relaciones con Inversores en TYRA BIOSCIENCES, INC. .

Health Technology

Perfil

Ms. Amy Conrad is a Founder & Chief Executive Officer at Juniper Point, Inc. and a Head-Investor Relations at Tyra Biosciences, Inc. Ms. Conrad was previously employed as a Head-Investor Relations by Anadys Pharmaceuticals, Inc., a Head-Investor Relations by Bionano Genomics, Inc., and an Investor Relations & Media Contact by Regulus Therapeutics, Inc.

Cargos activos de Amy Conrad

Empresas	Cargo	Inicio
TYRA BIOSCIENCES, INC.	Contacto de Relaciones con Inversores	-
Juniper Point, Inc.	Director Ejecutivo	-

Todos los cargos activos de Amy Conrad

Antiguos cargos conocidos de Amy Conrad.

Empresas	Cargo	Fin
REGULUS THERAPEUTICS INC.	Contacto de Relaciones con Inversores	01/01/2016
BIONANO GENOMICS, INC.	Contacto de Relaciones con Inversores	-
Anadys Pharmaceuticals, Inc. Anadys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Anadys Pharmaceuticals, Inc. develops and manufactures novel small molecule medicines. It engages in developing novel medicines in the areas of hepatitis C and oncology. The firm develops ANA598, a direct-acting antiviral for the treatment of hepatitis C. The company was founded by Stelios B. Papadopoulos and Kleanthis G. Xanthopoulos in 1992 and is headquartered in Little Falls, NJ.	Contacto de Relaciones con Inversores	-

Ver el detalle de la experiencia de Amy Conrad.

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Ver el detalle de la experiencia de Amy Conrad.

Relaciones

Relaciones de 1er grado

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Consultar la red personal

Empresas relacionadas

Empresas cotizadas	3
BIONANO GENOMICS, INC.	Health Technology
REGULUS THERAPEUTICS INC.	Health Technology
TYRA BIOSCIENCES, INC.	Health Technology

Empresas privadas	2
Anadys Pharmaceuticals, Inc. Anadys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Anadys Pharmaceuticals, Inc. develops and manufactures novel small molecule medicines. It engages in developing novel medicines in the areas of hepatitis C and oncology. The firm develops ANA598, a direct-acting antiviral for the treatment of hepatitis C. The company was founded by Stelios B. Papadopoulos and Kleanthis G. Xanthopoulos in 1992 and is headquartered in Little Falls, NJ.	Health Technology
Juniper Point, Inc.